# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Irène Joliot-Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB003-SYN
- Date: 2026-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Solène Marchand-Ellis, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit during treatment for acute myeloid leukemia. **S**

## History of present illness

Mrs. Joliot-Curie is a 58-year-old physicist with acute myeloid leukemia, on day 29 of her first cycle of azacitidine with venetoclax, who comes for her yearly preventive visit, which she asked to keep. The nausea and constipation settled within a few days. She has had no fever. The day-22 marrow showed no leukemia under the microscope, and venetoclax is on hold while her counts recover. She is tired but walks a little every day and reads papers from her laboratory at home. She has met the palliative care team twice and the transplant center once. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 58, during AML therapy |
| Leukemia | Day 29 of cycle 1; leukemia-free marrow on day 22; venetoclax on hold for count recovery |
| Mood | PHQ-2 1; GAD-7 5 |

## Health risk assessment

Completed by the patient on paper in the waiting room and reviewed with her by Dr. Marchand-Ellis. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair; better than a month ago |
| Psychosocial | Close family and colleagues; worries about her laboratory and her students; no financial strain she wishes to discuss |
| Substance use | AUDIT-C 1; no drug use |
| Tobacco | Never uses tobacco |
| Physical activity | Short walks daily |
| Nutrition | Eating small frequent meals; follows food-safety advice for neutropenia |
| Sleep | Six to seven hours |
| Safety | Wears a seat belt; no firearm at home; feels safe at home |
| Occupational | Off work in the laboratory during treatment; dose records requested from her employer |
| Activities of daily living | Independent; needs rest after climbing stairs |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever, chills or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No mouth sores; gum oozing has stopped |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Positive | Breathless on one flight of stairs, as before; no cough |
| Gastrointestinal | Negative | Nausea gone; bowels regular |
| Genitourinary | Negative | No urinary symptoms; periods ended in her early fifties |
| Musculoskeletal | Negative | No bone pain |
| Integumentary | Positive | Fading bruises on the shins |
| Neurological | Negative | No headache, numbness or confusion |
| Hematologic and lymphatic | Positive | Easy bruising, improving |
| Psychiatric | Negative | Mood steady; PHQ-2 1, GAD-7 5 |

12 systems reviewed. **S**

## Current medications

- Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle **S**
- Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic **S**
- Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis **S**
- Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 **S**
- Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/70 mmHg; pulse 86 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 53.2 kg; BMI 20 kg/m². All vital signs are synthetic.

PHQ-2: 1; GAD-7: 5; AUDIT-C: 1. All results are synthetic.

## Immunizations given today

- Influenza vaccine, inactivated, this season **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Tired but well; weight 53.2 kg, BMI 20.0; blood pressure 116/70 |
| Skin | Fading bruises on the shins; no petechiae; no suspicious moles |
| Mouth | No ulcers or thrush; teeth in good repair |
| Neck | No nodes; thyroid normal |
| Cardiovascular | Regular rhythm; no murmur; no ankle edema |
| Respiratory | Fine crackles at the right apex, unchanged; otherwise clear |
| Abdomen | Soft and non-tender; no enlarged liver or spleen |
| Breasts | No masses or skin change |
| Psychiatric | Composed and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed during AML therapy**. Health risk assessment reviewed and the prevention plan adjusted for active leukemia treatment: inactivated influenza vaccine given today; cancer screening and most other vaccines deferred, with the reasons recorded; HIV and hepatitis screening already done before treatment. **S**
   - Revisit deferred screening and vaccines after treatment, or on the transplant center's schedule.
   - Next preventive visit in one year.
2. **Acute myeloid leukemia, day 29 of cycle 1** (C92.00). Recovering from the nadir without infection. Response assessment and the cycle 2 decision at the review in four days. **S**
   - Continue prophylaxis and the fever plan.
   - Review with Dr. Engquist-Mensah's team in four days.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 116/70 mmHg |
| Depression screening | Completed today | PHQ-2 score 1 |
| Anxiety screening | Completed today | GAD-7 score 5, mild; supported by the palliative care team |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 1 |
| Tobacco use | Completed today | Never uses tobacco |
| HIV screening | Up to date | Negative before treatment |
| Hepatitis C screening | Up to date | Negative before treatment |
| Breast cancer screening | Due | Biennial mammography is due; deferred during induction and revisited after treatment or before transplant |
| Cervical cancer screening | Due | Last HPV test about four years ago, negative; due next year; deferred while counts are low |
| Colorectal cancer screening | Due | Colonoscopy about six years ago was normal; next due in four years; no test now while platelets are low |
| Lipid screening and statin assessment | Due | Deferred during induction; to be discussed after treatment |
| Diabetes screening | Not indicated | Not overweight; glucose normal on her chemistry panels |
| Lung cancer screening | Not indicated | Never smoked |
| Osteoporosis screening | Not indicated | Routine screening begins at 65; to be reconsidered before transplant because of the glucocorticoids and bone loss it can bring |
| Influenza vaccine | Completed today | Inactivated vaccine; household contacts should also be vaccinated |
| COVID-19 vaccine | Ordered | This season's vaccine ordered for the next infusion visit |
| Pneumococcal vaccine | Due | Recommended at 50 and over; deferred until at least three months after chemotherapy, or given on the transplant center's revaccination schedule, when it will work |
| Recombinant zoster vaccine | Due | Recommended at 50 and over; deferred until after treatment or as part of post-transplant revaccination; acyclovir prophylaxis in the meantime |
| Tetanus, diphtheria, and pertussis | Due | Last booster about eight years ago; next due in two years, after treatment |
| Hepatitis B vaccine | Due | Not immune on pre-treatment testing (all three markers negative); vaccinate after treatment or on the transplant schedule |
| Live vaccines | Not indicated | Contraindicated during AML therapy |
| Dental examination | Completed today | Dental check before treatment found no infection; soft brush while platelets are low |

## Advance care planning

Voluntary advance care planning discussion of about 30 minutes, with her consent, building on her first meeting with the palliative care team. She understands that her leukemia is high risk and that a transplant offers the best chance of long remission but carries its own risks. She wants full treatment, including intensive care, while there is a reasonable chance of returning to a life she values, which for her means being able to think, read and talk about her work; she would not want prolonged life support if that were no longer possible. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed an advance directive. To be revisited at each change in her illness. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026), National Comprehensive Cancer Network
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024), American Society of Clinical Oncology
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Response review and cycle 2 decision in four days. COVID-19 vaccine at the next infusion visit. Deferred screening and vaccines to be revisited after treatment or before transplant. Next preventive visit in one year. **S**
- Next scheduled visit 2026-10-30: count recovery and response assessment; cycle 2; transplant evaluation; occupational dose records. **S**
